Author:
Klein Thomas,Fujii Masato,Sandel Jan,Shibazaki Yuichiro,Wakamatsu Kyoko,Mark Michael,Yoneyama Hiroyuki
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,General Medicine,Pathology and Forensic Medicine
Reference43 articles.
1. Klein T, Mark M, Schuppan D (2011) The dipeptidyl peptidase 4 inhibitor linagliptin is an effective therapeutic for metabolic liver disease in several rodent models of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Hepatology 54(4(Suppl)):369A
2. Klein T, Mark M (2012) Linagliptin is an effective therapeutic for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Diabetes 61(Suppl 1):A265
3. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231
4. Nugent C, Younossi ZM (2007) Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 4:432–441
5. Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH (2010) The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 30:795–808
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献